Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Cardiovasc Drugs ; 19(1): 1-10, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30345485

ABSTRACT

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades. According to recent and promising studies, sacubitril/valsartan (SV) might be efficient in alternative indications in the area of HF with preserved left ventricular ejection fraction, chronic kidney disease, and so on. This review briefly summarizes these promising therapeutic options regarding SV and the potential limits and pitfalls for its use in routine practice (due to cognitive uncertainties).


Subject(s)
Aminobutyrates/pharmacology , Aminobutyrates/therapeutic use , Angiotensin Receptor Antagonists/pharmacology , Tetrazoles/pharmacology , Tetrazoles/therapeutic use , Valsartan/pharmacology , Valsartan/therapeutic use , Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Animals , Biphenyl Compounds , Drug Combinations , Heart Failure/drug therapy , Humans , Stroke Volume/drug effects , Ventricular Dysfunction, Left/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...